1. Reducing the Burden of Stage B Heart Failure and the Global Pandemic of Cardiovascular Disease: Time to Go to War with the “Barefoot” Troops! 
Ragavendra R. Baliga, MD, MBA 
Heart Failure Clinics 
Volume 8, Issue 2, Pages ix-xiii (April 2012)
DOI: /j.hfc
Copyright © 2012 Elsevier Inc. Terms and Conditions

2. Fig. 1 Stage A and stage heart failure: overview.
(Adapted from Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154–235; with permission.)
Heart Failure Clinics 2012 8, ix-xiiiDOI: ( /j.hfc )
Copyright © 2012 Elsevier Inc. Terms and Conditions

3. Fig. 2 Pyramid of HF in population.
(From Young JB, Narula J. Prevention should take center stage. Cardiol Clin 2007;25(4):xi–xiii; with permission.)
Heart Failure Clinics 2012 8, ix-xiiiDOI: ( /j.hfc )
Copyright © 2012 Elsevier Inc. Terms and Conditions

4. Fig. 3
Change over time in mean BMI, systolic blood pressure, and total cholesterol by countries’ income category: BMI is increasing in all three economic categories. In high-income countries, blood pressure and total cholesterol are decreasing. In middle-income countries, there is no major change in blood pressure and total cholesterol is decreasing. In low-income countries, blood pressure is increasing and total cholesterol is decreasing.13
(From Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet 2011;377(9765):530. [ with permission.)
Heart Failure Clinics 2012 8, ix-xiiiDOI: ( /j.hfc )
Copyright © 2012 Elsevier Inc. Terms and Conditions

5. Fig. 4
Number of drugs taken by patients with coronary artery disease by country economic status. The drugs counted were aspirin, β-blockers, ACE inhibitors or ARBs, or statins.
(From Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378(9798):1231–43; with permission.)
Heart Failure Clinics 2012 8, ix-xiiiDOI: ( /j.hfc )
Copyright © 2012 Elsevier Inc. Terms and Conditions

6. Ragavendra R. Baliga, MD, MBA, Consulting Editor
Heart Failure Clinics 2012 8, ix-xiiiDOI: ( /j.hfc )
Copyright © 2012 Elsevier Inc. Terms and Conditions

7. James B. Young, MD, Consulting Editor
Heart Failure Clinics 2012 8, ix-xiiiDOI: ( /j.hfc )
Copyright © 2012 Elsevier Inc. Terms and Conditions